STUDY DESIGN AND METHODS:
This study was a retrospective analysis of critically ill patients admitted to the intensive care unit (ICU) of two hospitals in Australia who received one or more PLT transfusions from 2008 to 2014. Storage duration was approached in several different ways. Outcome variables were hospital mortality and ICU-acquired infection. Associations between PLT storage duration and outcomes were evaluated using multiple logistic regression and also by Cox regression.
RESULTS:
Among 2250 patients who received one or more PLT transfusions while in the ICU, the storage duration of PLTs was available for 64% of patients (1430). In-hospital mortality was 22.1% and ICU infection rate 7.2%. When comparing patients who received PLTs of a maximum storage duration of not more than 3, 4, or 5 days, there were no significant differences in baseline characteristics. After confounders were adjusted for, the storage duration of PLTs was not independently associated with mortality (4 days vs. 
CONCLUSIONS:
In this large observational study in a heterogeneous ICU population, storage duration of PLTs was not associated with an increased risk of mortality or infection.
A pproximately 10% of all patients receive at least one platelet (PLT) transfusion while in the intensive care unit (ICU). 1 PLT transfusions are often administered to bleeding patients or as bleeding prophylaxis 2 in many of the 35% to 45% of ICU patients who have thrombocytopenia. 1, 3 PLTs must be stored in specific conditions at room temperature as their circulating time posttransfusion is ABBREVIATIONS: APACHE 5 Acute Physiology and Chronic Health Evaluation; HR 5 hazard ratio; ICU 5 intensive care unit; IQR 5 interquartile range. markedly reduced when cooled. [4] [5] [6] However, room temperature storage increases the risk of bacterial proliferation and is one of the main limitations of the maximum storage duration. 7, 8 Additionally, over their storage lifetime, PLTs undergo deleterious changes in their structure and function, thought to correspond with reduced hemostatic efficacy, 9 and these changes are often referred to as the PLT storage lesion. 4 Due to these two main factors (bacterial contamination and the development of a storage lesion), PLTs only have a usable shelf life of up to 5 days in Australia and up to 7 days in other parts of the world. 10 However, despite these in vitro indices, the clinical impact of storage duration on clinical outcomes remains unknown. We hypothesized that patients with critical illness (with its accompanying reduced physiologic reserve and high mortality) might, logically, be at a higher risk of adverse outcomes if prolonged PLT storage is detrimental. Only two previous studies have been conducted in critically ill patient populations and the results are conflicting.
11,12
Over the past decade there has been a substantial increase in demand for PLTs around the world. 13 The short duration of PLT storage creates a difficult to manage trade-off between minimizing wastage of expired PLTs and having sufficient supply to meet demand. Consequently, PLT wastage due to outdating can be as high as 15% to 30% of all PLT stocks. 8, 14 ICU patients are the third largest consumer of PLTs behind hematology and cardiac surgery patients. 13 If the storage duration of PLTs can be extended without impacting patient outcomes, better use could be made of this scarce resource. Accordingly, the purpose of this study was to investigate the association of PLT storage duration with mortality and ICU-acquired infection in a large heterogeneous population of critically ill patients at two teaching hospitals in Australia. If storage for up to 5 days has no impact on clinical outcomes, investigation of the effects of more prolonged storage would be justified, especially as PLTs of up to 7 days storage duration are already in use in some countries. 10 
MATERIALS AND METHODS

Study design
We performed a retrospective study of patients admitted to the ICUs of the Alfred and Austin Hospitals (Melbourne, Australia) between January 2008 and September 2013. The Austin Hospital has a 29-bed multidisciplinary ICU specializing in spinal trauma and liver transplant. The Alfred Hospital multidisciplinary ICU has a mean occupancy of 39 patients and specializes in trauma, heart, and lung transplantation and extracorporeal membrane oxygenation. Patients who received a PLT transfusion during ICU admission were included in the study. For patients with multiple ICU admissions during that hospital admission, only the first admission was considered.
Data collection
Data were obtained from prospectively maintained clinical databases and blood transfusion databases. Clinical data were extracted from local ICU databases used to collect and submit data to the Australian and New Zealand Intensive Care Society (ANZICS) adult patient database. This included sex, date of birth, comorbidities, ICU admission diagnosis, ICU and hospital admission and discharge dates, Acute Physiology and Chronic Health Evaluation (APACHE) III score, requirement for mechanical ventilation or renal replacement therapy, and ICU and hospital mortality.
Data on transfused blood components came from the hospital laboratory information system at each hospital. This included the type of product issued (PLTs, red blood cells [RBCs] , fresh-frozen plasma [FFP] , and cryoprecipitate), a unique donation identification number, and date and time of issue from the blood bank. The date of donation and PLT manufacture was provided by the Australian Red Cross Blood Service using the unique donation identification number. The age of the PLT component was calculated using the date of issue and transfusion from the hospital laboratory and date of manufacture.
PLT units are manufactured by two methods in Australia: either by apheresis from anticoagulated blood separated into components to produce apheresis PLTs or from the buffy coats of whole blood from four donors of identical ABO blood type to produce pooled PLTs. 15 Both apheresis and pooled PLTs are resuspended in PLT additive solution and are leukoreduced before being stored for up to 5 days at 20 to 248C with gentle continuous agitation. 15 Infection data were obtained from the microbiology laboratory records at the Austin Hospital and from the Alfred Hospital's prospectively maintained infectious disease database. This included the dates of positive blood cultures and positive urine cultures, and their isolated pathogens. If a known contaminant was isolated, only results with two or more positive blood cultures were included.
Data analysis
The primary outcomes were hospital mortality and ICUacquired infection. Hospital mortality was defined as death while an inpatient in the hospital. ICU-acquired infection was defined as bacteremia and/or bacteriuria occurring 48 hours after ICU admission until ICU discharge. The storage duration of PLTs was considered in four different ways: the maximum (oldest unit), minimum (youngest unit), and median storage duration of all PLTs transfused and the storage duration of the first PLT unit transfused. We hypothesized that the maximum storage duration would be the most likely to be associated with outcomes if a relationship was to be found. The median storage duration was analyzed because storage duration distribution was skewed toward more prolonged storage and the cumulative storage duration may be important for multiple PLT unit ages. The minimum storage duration and the storage duration of the first unit transfused were included for comparison. A secondary analysis was performed analyzing patients who received only one PLT transfusion; we did this to facilitate comparison with previous studies.
Statistical analysis
Descriptive statistics are reported according to data distribution as either mean (6standard deviation [6SD]) or median (interquartile range [IQR]). Hypothesis testing was performed using t test and analysis of variance for normally distributed variables, Kruskal-Wallis test for nonnormally distributed data, and chi-square or Fisher's exact test for categorical variables. The relationship between storage duration and outcomes was analyzed using a logistic regression with the treatment variable being a categorical variable of not more than 3, 4, or 5 days. Results are reported using odds ratios (ORs; 95% confidence interval [CI] ). Multivariate analysis was performed adjusting for the following confounders: sex, APACHE III score, site, diagnosis category, year, requirement for renal replacement therapy, requirement for mechanical ventilation, and whether another type of transfusion (RBC, FFP, or cryoprecipitate) had been given before the PLT transfusion. A two-sided significance level of p 5 0.05 was considered to indicate significance. Survival time was estimated using the Kaplan-Meier method, and the log rank test was used to compare survival between groups. Association between PLT storage and survival was modeled using Cox regression, adjusting for sex, APACHE III score, site, diagnosis category, year, requirement for renal replacement therapy, requirement for mechanical ventilation, and blood components (RBCs, FFP, or cryoprecipitate) treated as timevarying variables. All analyses were performed using computer software (STATA, Version 12.1, StataCorp). 16 The study was approved by the human research ethics committees at both sites.
RESULTS
Of the 19,101 patients admitted to the ICUs of the two hospitals between January 2008 and September 2013, there were complete data (ICU, transfusion, and microbiology) for 18,965 (99%) patients. Of these, 2250 (12%) patients received at least one PLT transfusion in the ICU, and the storage duration of PLTs was available for 1430 (64%) patients (Fig. 1) . Table 1 shows comparison demographics between those where PLT storage duration was known versus those where PLT storage duration was unavailable.
In total, 4238 PLT units were transfused during the study period for which the storage duration was known. The PLT storage duration ranged from 2 to 5 days, with mean (6SD) storage duration of 4 (61) days, median storage duration of 4 days (IQR, 3 to 5 days), and most common storage duration of 5 days (41% of transfusions; Fig.  2 ). The donor ABO and Rhesus group was recorded for 57% of transfusions, of which 36% were blood group A, 3% group B, and 61% group O and 70% were D1. A total of 3599 (85%) of all PLT units transfused were pooled PLTs manufactured from whole blood and 649 (15%) were apheresis PLTs. Of the first PLT unit transfused, 87% were pooled PLTs. Table 2 shows demographics, ICU admission diagnosis, pre-ICU comorbidities, and ICU treatment variables for patient groups by the maximum storage duration of PLTs transfused and for all patients. The mean (6SD) age of patients was 58 (619) years. The population was predominantly male (67%) and the mean (6SD) APACHE I I I score was 66 (629). There were no significant differences between patient groups except that patients receiving fresher PLTs were more likely to be insulin-dependent diabetics (p 5 0.02).
Maximum storage duration of PLTs
Seventy-nine percent of patients received at least one RBC transfusion, 67.8% received FFP, and 29.2% received cryoprecipitate (Table 3 ). There were no significant differences in the median units of any blood products between PLT age groups.
The overall in-hospital mortality was 22.1% and ICUacquired infection rate was 7.2% (Table 4) . Hospital mortality and infection rates were similar in PLT storage categories in the univariate analysis, with no significant difference between groups for mortality (p 5 0.47) and infection (p 5 0.44).
After confounders were adjusted for, there was no significant difference in mortality between PLT storage groups (4 days vs. 3 days, OR 0.88, 95% CI, 0.59-1.30; 5 days vs. 3 days, OR 0.97, 95% CI 0.68-1.37). Similarly, no significant differences were found in the rates of infection (bacteremia and/or bacteriuria) both in the univariate analysis (p 5 0.44) and after adjusting for confounders ( 
Subgroup analyses
To confirm that these findings were consistent across different patient groups, subgroup analyses were performed on trauma patients, hematology patients, nonhematology patients, those receiving other transfusions, and those not receiving other transfusions, stratified between the most critically ill 50% and the least critically ill 50% as measured by the APACHE III score and considering postoperative cardiac patients as a proxy for cardiac surgery patients. The storage duration of PLTs was not associated with an increased risk of mortality or infection in any of these subgroups, with the exception that in the postoperative cardiac subgroup, PLTs of 4-day storage duration were associated with a lower risk of mortality compared to 3 days but not observed for 5 days compared to 3 days. A subgroup analysis of infection in hematology patients was not performed due to insufficient outcomes.
DISCUSSION
We found that the storage duration of PLTs (up to 5 days) was not associated with hospital mortality or infection in a large population of critically ill patients. These results were independent of the PLT storage duration variable used (the maximum, minimum, median, or first storage duration of PLTs transfused) and independent within the subgroup analyses and in those who received only a single PLT transfusion.
Comparison with existing literature
There have only been two studies examining the effect of PLT storage duration on patient outcomes in critical care.
In a retrospective study of 2578 cardiac surgery patients receiving PLTs, Welsby and colleagues 12 concluded that storage duration was not associated with adverse shortterm outcomes, long-term survival, or infection. In a retrospective study of trauma patients receiving PLTs, Inaba and coworkers 11 found that storage duration was not associated with mortality; however, there was a stepwise increase in the rates of sepsis with increasing storage duration. Our findings do not support an association between PLT storage up to 5 days and infection as in Inaba and colleagues, 11 who investigated a more homogeneous population of 381 trauma patients at a single center with higher rates of infection overall, reporting sepsis rates of 10.8% compared to an overall infection of 7.2% in our study. In a post hoc analysis of the Platelet Dose (PLADO) study 17 of hematology-oncology patients, Kaufman and coworkers 18 found that the storage duration of PLTs up to 5 days was not associated with an increased risk of transfusion-related adverse events including infection.
The impact of storage duration on other outcomes such as bleeding, corrected PLT count increments, and time to next transfusion remains uncertain. In one retrospective cohort study of hematology patients, shorter storage duration was associated with increased corrected count increments (CCIs) and lower bleeding events. 19 In a randomized noninferiority crossover trial of hematology patients, MacLennan and colleagues 10 found that 6-to 7-day-old PLTs were not inferior to 2-to 5-day-old PLTs as measured by posttransfusion CCIs, bleeding events, and the time to next transfusion. While our study did not examine CCIs or bleeding events, the observation that the total number of units transfused to patients receiving older PLTs was not significantly more than those receiving PLTs of shorter storage duration supports other study findings that the efficacy of prolonged storage PLTs is comparable.
Strengths and limitations
Our study has a number of strengths including its large sample size, multicenter design and inclusion of both whole blood-derived and apheresis PLTs, which contribute to the generalizability of our findings. In addition, to our knowledge it is the first study to investigate the storage duration of PLTs in a heterogeneous critically ill population and we were able to adjust for important confounders thought to be associated with outcomes. Our results were consistent regardless of how we defined the storage duration of PLTs (maximum, minimum, median, or the storage duration of the first unit), and there were no differences in effects in clinically relevant subgroups. Landmark outcomes and survival analyses reached similar conclusions. Limitations of this study include its retrospective and observational design. However, data came from prospectively maintained databases, so issues of bias should be minimal. While we did not find a significant association FLINT ET AL.
between PLT storage duration and outcomes, it is possible that our study was not sufficiently powered to detect significant benefit or harm. There was a proportion of PLT units for which we were unable to obtain donation date, and although patients excluded from the analysis due to missing PLT age data were similar with respect to illness severity, there were differences in age and comorbidities. While we adjusted for a range of important determinants of the outcomes of interest, we may have omitted other important confounders that were not available in our data. Infection data were limited to infections while in the ICU, so it is possible that we did not capture some infections occurring after ICU discharge. Furthermore, our definition of infection was limited to positive culture results; many patients with culture-negative clinically apparent infection would not have been identified. Finally, we had no data about PLTs and blood products received before ICU admission and so could not analyze the potential effect of these pre-ICU transfusions on outcomes.
Implications of the study findings
Our study implies that, up to Day 5, duration of PLT storage may not affect clinical outcomes. However, as with the previous studies investigating the impact of storage duration of PLTs on outcomes, this study only investigated association and not causality. Prospective research is warranted to determine whether storage duration of PLTs is associated with clinical-centered outcomes and therefore whether extending the storage duration could be achieved without adversely impacting on patient outcomes.
In conclusion, in this observational study of a heterogeneous population of critically ill patients, the storage duration of PLTs up to 5 days was not found to be associated with mortality or infection. Investigating the clinical effect of more prolonged storage is justified.
